Skip to Main Content

Paper Details

The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Diabetes Obes Metab
2
2023
Author NameAffiliation
Kenneth W MahaffeyStanford Centre for Clinical Research, Stanford University School of Medicine
  • 1 - 1

Datasets

Release 1.2